Introduction

SACUSMART 50 is a combination of Sacubitril 24 mg and Valsartan 26 mg, developed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Manufactured by Steris Healthcare, this innovative dual-acting therapy belongs to the class of angiotensin receptor neprilysin inhibitors (ARNI). It helps improve heart function, reduce hospitalizations, and lower the risk of cardiovascular death in heart failure patients. SACUSMART 50 is designed for effective, safe, and long-term management of heart failure symptoms.

Sacubitril and Valsartan Uses

SACUSMART 50 is primarily used for:

• Chronic Heart Failure (HFrEF): Improves symptoms and quality of life in patients with reduced ejection fraction.

• Reducing Cardiovascular Risk: Lowers the risk of death and hospitalizations due to heart failure.

This combination therapy is usually prescribed in patients who have not responded well to ACE inhibitors or ARBs alone.

Sacubitril Valsartan Mechanism of Action

• Sacubitril is a neprilysin inhibitor. It works by increasing the levels of natriuretic peptides, which promote vasodilation, natriuresis (excretion of sodium), and reduce cardiac remodeling.

• Valsartan is an angiotensin II receptor blocker (ARB). It blocks the effects of angiotensin II, leading to vasodilation, reduced blood pressure, and decreased cardiac workload.

Together, sacubitril and valsartan tablets enhance the protective neurohormonal systems while inhibiting the harmful effects of the renin-angiotensin-aldosterone system (RAAS).

Sacubitril Valsartan Dose and Administration

• Initial Dose: SACUSMART 50 (24 mg sacubitril + 26 mg valsartan) twice daily.

• Titration: The dose may be gradually increased to a maintenance dose (e.g., 97 mg/103 mg twice daily), based on patient tolerance and clinical response.

• Administration: Should be taken orally, with or without food.

Important: Discontinue ACE inhibitors at least 36 hours before starting sacubitril/valsartan to avoid angioedema.

Sacubitril Valsartan Side Effects

Common Side Effects:

• Dizziness or light-headedness

• Cough

• Fatigue

• Low blood pressure (hypotension)

• High potassium levels (hyperkalemia)

• Kidney function changes

Serious Side Effects:

• Angioedema (swelling of face/lips/tongue)

• Severe hypotension

• Renal impairment

Patients should be monitored regularly for electrolyte levels, renal function, and blood pressure.

Precautions and Warnings

• Avoid in pregnancy and lactation.

• Not recommended for patients with a history of angioedema related to ACE/ARB use.

• Use caution in patients with renal or hepatic impairment.

• Avoid combining with ACE inhibitors or aliskiren.

Storage Information

• Store at room temperature (below 25°C).

• Keep away from moisture and direct sunlight.

• Keep out of reach of children.

Why Choose SACUSMART 50 by Steris Healthcare?

Steris Healthcare is a reputed pharmaceutical company offering high-quality, affordable cardiovascular medicines. With WHO-GMP certified manufacturing and a pan-India presence, SACUSMART 50 delivers both therapeutic efficacy and safety to support heart failure management.

FAQs

Q. Is SACUSMART 50 the same as Entresto?
Yes, SACUSMART 50 is a generic equivalent of Entresto, containing the same combination of sacubitril and valsartan.

Q. How long should I take sacubitril and valsartan tablets?
This medication is typically taken long-term under medical supervision for heart failure management.

Q. Can I stop SACUSMART 50 if I feel better?
No, stopping the medication without consulting your doctor can increase the risk of heart failure complications.

Conclusion

SACUSMART 50, containing sacubitril 24 mg and valsartan 26 mg, is a breakthrough therapy for managing chronic heart failure with reduced ejection fraction. Its dual mechanism offers superior cardiovascular protection, fewer hospitalizations, and better quality of life for patients. Always follow your cardiologist's instructions and regular check-ups while using sacubitril and valsartan tablets. With SACUSMART 50, trust Steris Healthcare to keep your heart stronger and healthier.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW

News Referrences: 

• Mumbai Based Steris Healthcare Announces Expansion Plan IPO Launch: msn.com 
• Steris Healthcare Unveils Rs 50 Crore Expansion Plan, Eyes IPO In FY 2026-27 :  bwhealthcareworld.com
• Mumbai-based Steris Healthcare Pvt Ltd plans to launch IPO in FY 2026-27: indianstartupnews.com
• Steris Healthcare Announces Rs 50 Crore Expansion, IPO Planned For FY 2026-27 : News18.com
• Steris Healthcare Pvt Ltd announces ₹50 crore expansion and IPO plans for FY 2026–27:  expresspharma.com

Steris Healtcare: Our Brand Is List On Trusted News Platform.
Steris Healthcare, a pharmaceutical company headquartered in Mumbai, has announced a strategic expansion plan worth ₹50 crore. The initiative includes setting up a new manufacturing facility in South India, doubling its current production capacity, and preparing for an Initial Public Offering (IPO) scheduled for the financial year 2026–27.

Having surpassed ₹100 crore in annual sales, Steris Healthcare aims to strengthen its nationwide footprint by expanding into key southern markets such as Kerala, Tamil Nadu, Telangana, and Karnataka. The upcoming manufacturing unit is expected to play a crucial role in enhancing the company's production capabilities and meeting the rising demand from both domestic and international markets.